Management of atherogenic dyslipidemia of the metabolic syndrome: Evolving rationale for combined drug therapy

Endocrinology and Metabolism Clinics of North America

Volumn 33, Issue 3, 2004, Pages 525-544

  Vega, Gloria Lena ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; STANOL ESTER;

ABDOMINAL PAIN; ARTERIOSCLEROSIS; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL STONE; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG INFORMATION; DRUG SAFETY; DRUG TARGETING; DRUG UTILIZATION; DYSLIPIDEMIA; DYSPEPSIA; ECZEMA; FATIGUE; FATTY ACID METABOLISM; FLUSHING; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; METABOLIC SYNDROME X; MYALGIA; MYOPATHY; NAUSEA; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUANTITATIVE ANALYSIS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION; VERTIGO; VOMITING;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; METABOLIC SYNDROME X;

EID: 3242664106     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2004.03.013     Document Type: Review

References (75)

1. ATP. III Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
2. Blades B., Vega G.L., Grundy S.M. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler Thromb. 13:(8):1993;1227-1235
3. Tato F., Vega G.L., Tall A.R., Grundy S.M. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 15:(1):1995;112-120
4. Tato F., Vega G.L., Grundy S.M. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients. Role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol. 17:(1):1997;56-63
5. Kawashiri M.A., Maugeais C., Rader D.J. High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. Curr Atheroscler Rep. 2:(5):2000;363-372
6. Barter P.J., Baker P.W., Rye K.A. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 13:(3):2002;285-288
7. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135
8. Aviram M. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins. Antioxid Redox Signal. 1:(4):1999;585-594
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:(2):1999;115-126
10. Nathan C.F. Secretory products of macrophages. J Clin Invest. 79:(2):1987;319-326
11. Mackness M.I., Abbott C., Arrol S., Durrington P.N. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 294:(Pt 3):1993;829-834
12. Xia P., Vadas M.A., Rye K.A., Barter P.J., Gamble J.R. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem. 274:(46):1999;33143-33147
13. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res. 40:(2):1999;345-353
14. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C. ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 88:(3):2001;265-269
15. Kulkarni K.R., Garber D.W., Marcovina S.M., Segrest J.P. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res. 35:(1):1994;159-168
16. Otvos J.D., Jeyarajah E.J., Bennett D.W., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 38:1992;1632-1638
17. Muniz N. Measurement of plasma lipoproteins by electrophoresis on polyacrylamide gel. Clin Chem. 23:(10):1977;1826-1833
18. Mahley R.W., Huang Y., Rall S.C. Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res. 40:(11):1999;1933-1949
19. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 52:(7):1973;1544-1568
20. McNeely M.J., Edwards K.L., Marcovina S.M., Brunzell J.D., Motulsky A.G., Austin M.A. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis. 159:(2):2001;471-481
21. Kissebah A.H., Alfarsi S., Evans D.J. Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis. 4:(6):1984;614-624
22. Vega G.L., Grundy S.M. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med. 230:(4):1991;341-350
23. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287:(3):2002;356-359
24. Fruchart J.C., Staels B., Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res. 44:(5):2001;345-352
25. Davignon J. The cardioprotective effects of statins. Curr Atheroscler Rep. 6:(1):2004;27-35
26. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
27. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009
28. The long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357
29. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307
30. Downs M. Jr., Clearfield S., Weis E., Whitney D.R., Shapiro P.A., Beere A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22
32. Pasternak R.C., Smith S.C. Jr., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 40:(3):2002;567-572
33. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418
34. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 357:2001;905-910
35. Koskinen P., Mänttäri M., Manninen V., Huttunen J.K., Heinonen O.P., Frick M.H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 15:1992;820-825
36. Kontopoulos A.G., Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Mayroudi M.C., Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 7:1996;843-850
37. East C., Bilheimer D.W., Grundy S.M. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 109:1988;25-32
38. Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Didangelos T.P., Carina M.V., Kranitsas D.F., et al. Safety and efficacy of long-term statin-fibrate combination in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 80:1997;608-613
39. Napoli C., Lepore S., Chiariello P., Condorelli M., Chiariello M. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia. J Cardiovasc Pharmacol Ther. 2:(1):1997;17-26
40. Vega G.L., Vega G.L., Ma P.T., Cater N.B., Filipchuk N., Meguro S., et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol. 91:(8):2003;956-960
41. Athyros V.G., Papageorgiou A.A., Hagikonstantinou H.J., Papadopoulos G.V., Zamboulis C.X., Kontopoulos A.G. Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidemia: a clinical study. Drug Invest. 7:(3):1994;134-142
42. Glueck C.J., Oakes N., Speirs J., Tracy T., Lang J. Gemfibrozil- lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol. 70:1992;1-9
43. Glueck C.J., Speirs J., Tracy T. Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias. J Lab Clin Med. 115:1990;603-609
44. Zambon D., Ros E., Rodriguez-Villar C., Laguna J.C., Vazquez M., Sanllehy C., et al. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism. 48:(1):1999;47-54
45. Yeshurun D., Abukarshin R., Elias N., Lanir A., Naschitz J.E. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Ther. 15:1993;355-363
46. Farnier M., Bonnefous F., Debbas N., Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med. 154:1994;441-449
47. Murdock D.K., Murdock A.K., Murdock R.W., Olson K.J., Frane A.M., Kersten M.E., et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 138:1999;151-155
48. Vega G.L., Grundy S.M. Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med. 150:(6):1990;1313-1319
49. Iliadis E.A., Rosenson R.S. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol. 22:(1):1999;25-28
50. Smit J.W., De Bruin T.W., Eekhoff E.M., Glatz J., Erkelens D.W. Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention. Metabolism. 48:(12):1999;1518-1523
51. Spieker L.E., Noll G., Hannak M., Luscher T.F. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharm. 35:2000;361-365
52. Deslypere J.P. Addition of fibrates to simvastatin therapy in hyperlipidemia patients. Atherosclerosis. 97:1992;S67-S71
53. Papadakis J.A., Ganotakis E.S., Jagroop I.A., Winder A.F., Mikhailidis D.P. Atatin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol. 69:1999;237-244
54. Garg A., Grundy S.M. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes. 38:(3):1989;364-372
55. Wagner A.M., Wagner A.M., Jorba O., Bonet R., Ordonez-Llanos J., Perez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 88:(7):2003;3212-3217
56. Guyton J.R. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol. 82:(12A):1998;18U-23U. [discussion: 39U-41U]
57. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2:(1):2000;36-46
58. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 8:1986;1245-1255
59. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:(5):1988;405-418
60. Cashin-Hemphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 264:1990;3013-3017
61. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:(19):1990;1289-1298
62. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:(23):1990;3007-3012
63. Brown B.G., Bardsley J., Poulin D., Hillger L.A., Dowdy A., Maher V.M., et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 80:(2):1997;111-115
64. Davignon J., Roederer G., Montigny M., Hayden M.R., Tan M.H., Connelly P.W., et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 73:(5):1994;339-345
65. Jacobson T.A., Chin M.M., Fromell G.J., Jokubaitis L.A., Amorosa L.F. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 74:(2):1994;149-154
66. Tsalamandris C., Panagiotopoulos S., Sinha A., Cooper M.E., Jerums G. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk. 1:(3):1994;231-239
67. Vacek J.L., Dittmeier G., Chiarelli T., White J., Bell H.H. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 76:(3):1995;182-184
68. O'Keefe J.H. Jr., Harris W.S., Nelson J., Windsor S.L. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 76:(7):1995;480-484
69. Gardner S.F., Schneider E.F., Granberry M.C., Carter I.R. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 16:(3):1996;419-423
70. Gardner S.F., Gardner S.F., Marx M.A., White L.M., Granberry M.C., Skelton D.R., et al. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother. 31:(6):1997;677-682
71. Pasternak R.C., Brown L.E., Stone P.H., Silverman D.I., Gibson C.M., Sacks F.M. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med. 125:(7):1996;529-540
72. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 89:2002;672-678
73. Garg A., Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 264:(6):1990;723-726
74. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., et al. Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 162:(14):2002;1568-1576
75. Vega G.L., Cater N.B., Hadizadeh D.R. 3rd, Meguro S., Grundy S.M. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther. 74:(3):2003;236-244